1. Home
  2. PIRS

PIRS

Pieris Pharmaceuticals Inc.

Logo Pieris Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Founded: N/A Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 15.5M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 616.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.27 EPS Growth: N/A
52 Week Low/High: $0.14 - $1.01 Next Earning Date: 05-08-2024
Revenue: $42,810,000 Revenue Growth: 65.28%
Revenue Growth (this year): -84.21% Revenue Growth (next year): N/A

Share on Social Networks: